IMVT - Immunovant, Inc.
27.08
0.370 1.366%
Share volume: 1,244,127
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$26.71
0.37
0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
| Report Date | 11-07-2024 | 08-06-2024 | 11-07-2024 | 02-06-2025 | 05-29-2025 | 08-11-2025 | 11-10-2025 | 02-06-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | |||||
| Operating expenses | 80.879 M | 94.281 M | 115.743 M | 114.302 M | 113.826 M | 127.224 M | 131.762 M | 114.362 M | |
| Selling general and admin | 14.823 M | 18.808 M | 18.471 M | 19.782 M | 20.174 M | 26.024 M | 17.513 M | 15.438 M | |
| Research and development | 66.056 M | 75.473 M | 97.272 M | 94.520 M | 93.652 M | 101.200 M | 114.249 M | 98.924 M | |
| Total expenses | 80.879 M | 94.281 M | 115.743 M | 114.302 M | 113.826 M | 127.224 M | 131.762 M | 114.362 M | |
| 16.57% | 22.76% | -1.24% | -0.42% | 11.77% | 3.57% | -13.21% | |||
| Operating income | -80.879 M | -94.281 M | -115.743 M | -114.302 M | -113.826 M | -127.224 M | -131.762 M | -114.362 M | |
| Ebit | -83.465 M | -94.253 M | -115.114 M | -115.560 M | -112.754 M | -126.037 M | -131.512 M | -114.416 M | |
| Pretax income | -75.087 M | -87.073 M | -109.041 M | -110.970 M | -105.865 M | -119.700 M | -125.908 M | -109.083 M | |
| 15.96% | 25.23% | 1.77% | -4.60% | 13.07% | 5.19% | -13.36% | |||
| Income tax | 232.000 K | 77.000 K | 78.000 K | 152.000 K | 584.000 K | 913.000 K | 594.000 K | 1.552 M | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -75.319 M | -87.150 M | -109.119 M | -111.122 M | -106.449 M | -120.613 M | -126.502 M | -110.635 M | |
| -15.71% | -25.21% | -1.84% | 4.21% | -13.31% | -4.88% | 12.54% |